Features include always present findings: Abdominal obesity and Hypertension; and very common findings: Myocardial infarction and Type II diabetes mellitus. 11 total HPO annotations.

DYRK1B encodes dual specificity tyrosine phosphorylation regulated kinase 1B (629 aa). Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. Highest expression in Testis (166.9 TPM) and Muscle Skeletal (70.3 TPM).

Abdominal obesity-metabolic syndrome 3 is associated with mutations in the DYRK1B gene on chromosome 19.

DYRK1B is classified as a druggable target (Dna Repair, Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 1.4.

Genetic testing for DYRK1B is available. Testing is considered confirmatory for diagnosis.

Phenotype severity distribution: 2 always present features, 2 very common features, 2 common features.

No clinical trials have been registered for abdominal obesity-metabolic syndrome 3.

4 publications have been identified in PubMed for abdominal obesity-metabolic syndrome 3. Research spans Basic Science / Preclinical (50%), Case Report / Case Series (25%), and Epidemiology / Natural History (25%).

Recent Publications

• Li S (2025). [PMID: 40287828](https://pubmed.ncbi.nlm.nih.gov/40287828/). *Nucleic acids research*. [Basic Science / Preclinical]

• Hui H (2025). [PMID: 40329189](https://pubmed.ncbi.nlm.nih.gov/40329189/). *BMC pediatrics*. [Epidemiology / Natural History]

• Radi S (2024). [PMID: 39108603](https://pubmed.ncbi.nlm.nih.gov/39108603/). *JCEM case reports*. [Case Report / Case Series]

• Detro-Dassen S (2024). [PMID: 38867326](https://pubmed.ncbi.nlm.nih.gov/38867326/). *Orphanet journal of rare diseases*. [Basic Science / Preclinical]